Tien Liang BioTech Co., Ltd.
Taipei ExchangeTotal Valuation
Tien Liang BioTech Co., Ltd. carries a market capitalization of 3.51B, placing it among publicly traded companies globally. Its enterprise value stands at 1.87B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.51B |
| Enterprise Value | 1.87B |
Share Statistics
Tien Liang BioTech Co., Ltd. currently has 45.76M shares outstanding.
| Shares Outstanding | 45.76M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Tien Liang BioTech Co., Ltd. trades at a trailing price-to-earnings ratio of 58.90. The price-to-sales ratio is 2.77, and the price-to-book ratio stands at 3.07.
| PE Ratio | 58.90 |
| PS Ratio | 2.77 |
| PB Ratio | 3.07 |
| P/TBV Ratio | 3.00 |
| P/FCF Ratio | 33.48 |
| P/OCF Ratio | 73.85 |
Enterprise Valuation
On an enterprise value basis, Tien Liang BioTech Co., Ltd. trades at an EV/EBITDA multiple of 2,611.65 and an EV/FCF ratio of 35.80. The EV/Sales ratio of 3.65 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 2,611.65 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.65 |
| EV / EBITDA | 2,611.65 |
| EV / EBIT | 2,611.65 |
| EV / FCF | 35.80 |
Financial Position
Tien Liang BioTech Co., Ltd. maintains a current ratio of 0.40, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 126.26, indicating elevated leverage, while an interest coverage ratio of -1.45 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.40 |
| Quick Ratio | 0.21 |
| Debt / Equity | 126.26 |
| Debt / EBITDA | -37.08 |
| Interest Coverage | -1.45 |
Financial Efficiency
| Return on Equity (ROE) | -2.16 |
| Return on Assets (ROA) | -0.99 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 0.89 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.57 |
Taxes
Over the trailing twelve months, Tien Liang BioTech Co., Ltd. has paid -1.50M in income taxes, reflecting an effective tax rate of 1.91.
| Income Tax | -1.50M |
| Effective Tax Rate | 1.91 |
Stock Price Statistics
Tien Liang BioTech Co., Ltd.'s stock has gained approximately 112.76006% over the past 52 weeks. The 50-day moving average sits at 57.31, while the 200-day moving average is 39.87.
| Beta (5Y) | N/A |
| 52-Week Price Change | 112.76006% |
| 50-Day Moving Average | 57.31 |
| 200-Day Moving Average | 39.87 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Tien Liang BioTech Co., Ltd. generated 511.79M in revenue and converted that into -10.25M in net income, yielding earnings per share of -0.22. EBITDA reached -16.14M, while operating income came in at -16.14M.
| Revenue | 511.79M |
| Gross Profit | 287.94M |
| Operating Income | -16.14M |
| Pretax Income | -11.75M |
| Net Income | -10.25M |
| EBITDA | -16.14M |
| EBIT | -16.14M |
| Earnings Per Share (EPS) | -0.22 |
Balance Sheet
Tien Liang BioTech Co., Ltd. holds 152.31M in cash and equivalents against 598.54M in total debt, resulting in a net debt position of 476.23M. Total book value stands at 462.66M, with working capital of -423.77M providing operational flexibility.
| Cash & Cash Equivalents | 152.31M |
| Total Debt | 598.54M |
| Net Debt | 476.23M |
| Equity (Book Value) | 462.66M |
| Book Value Per Share | 10.10 |
| Working Capital | -423.77M |
Cash Flow
Tien Liang BioTech Co., Ltd. produced 19.23M in operating cash flow over the past twelve months. After subtracting -23.19M in capital expenditures, free cash flow totaled -3.96M - equivalent to -0.09 per share.
| Operating Cash Flow | 19.23M |
| Capital Expenditures | -23.19M |
| Free Cash Flow | -3.96M |
| FCF Per Share | -0.09 |
Margins
Tien Liang BioTech Co., Ltd. operates with a gross margin of 56.26, reflecting its pricing power and cost economics. The operating margin of -3.15 and net profit margin of -2.00 provide insight into operational efficiency.
| Gross Margin | 56.26 |
| Operating Margin | -3.15 |
| Pretax Margin | -2.30 |
| Profit Margin | -2.00 |
| EBITDA Margin | -3.15 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -17.89 |
| FCF Yield | 2.99 |
Stock Splits
Tien Liang BioTech Co., Ltd.'s most recent stock split took place on September 24, 2008 with a 25:26 split ratio.
| Last Split Date | 9/24/2008 |
| Split Ratio | 25:26 |
Scores
Tien Liang BioTech Co., Ltd. posts an Altman Z-Score of 1.17, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.17 |